


PRODUCT INFORMATION



Parvodicin C₂ Item No. 32542

CAS Registry No.: 110882-85-4
Formal Name: 5,31-dichloro-7-demethyl-64-O-demethyl-19-deoxy-56-O-[2-deoxy-2-[(1-oxododecyl)amino]-β-D-glucopyranuronosyl]-42-O-α-D-mannopyranosyl-N¹⁵-methyl-ristomycin A aglycone

Synonym: Antibiotic A40926 B₁
MF: C₈₃H₈₈Cl₂N₈O₂₉
FW: 1,732.5
Purity: ≥90%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years
Item Origin: Synthetic



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Parvodicin C₂ is supplied as a crystalline solid. A stock solution may be made by dissolving the parvodicin C₂ in the solvent of choice, which should be purged with an inert gas. Parvodicin C₂ is soluble in the organic solvent DMSO at a concentration of approximately 10 mg/ml.

Parvodicin C₂ is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, parvodicin C₂ should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Parvodicin C₂ has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Parvodicin C₂ is a glycopeptide antibiotic originally isolated from *A. parvosata* and a component of parvodicin complex (Item No. 24036).¹ It is also a component of the A40926 antibiotic complex, which has been used as a precursor in the synthesis of the antibiotic dalbavancin (Item No. 21161).² Parvodicin C₂ is active against methicillin-sensitive strains of *S. aureus*, *S. epidermidis*, and *S. saprophyticus* (MICs = 0.4-12.5 µg/ml), as well as methicillin-resistant strains of *S. aureus*, *S. hemolyticus*, and *E. faecalis* (MICs = 0.2-50 µg/ml).¹

References

1. Christensen, S.B., Allaudeen, H.S., Burke, M.R., *et al.* Parvodicin, a novel glycopeptide from a new species, *Actinomadura parvosata*: Discovery, taxonomy, activity and structure elucidation. *J. Antibiot. (Tokyo)* **40(7)**, 970-990 (1987).
2. Jovetic, S., Feroggio, M., Marinelli, F., *et al.* Factors influencing cell fatty acid composition and A40926 antibiotic complex production in *Nonomuraea sp.* ATCC 39727. *J. Ind. Microbiol. Biotechnol.* **35(10)**, 1131-1138 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/03/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM